Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 23, 2017

DrugPatentWatch Database Preview

TRIPELENNAMINE HYDROCHLORIDE Drug Profile

« Back to Dashboard

Which patents cover Tripelennamine Hydrochloride, and what generic Tripelennamine Hydrochloride alternatives are available?

Tripelennamine Hydrochloride is a drug marketed by Nylos, Watson Labs, Parke Davis, Anabolic, Barr, Lannett, Impax Labs, and Heather. and is included in eleven NDAs.

The generic ingredient in TRIPELENNAMINE HYDROCHLORIDE is tripelennamine hydrochloride. There is one drug master file entry for this compound. Additional details are available on the tripelennamine hydrochloride profile page.

Summary for Tradename: TRIPELENNAMINE HYDROCHLORIDE

Patents:0
Applicants:8
NDAs:11
Bulk Api Vendors: see list40
Clinical Trials: see list988
Patent Applications: see list570
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:TRIPELENNAMINE HYDROCHLORIDE at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Nylos
TRIPELENNAMINE HYDROCHLORIDE
tripelennamine hydrochloride
TABLET;ORAL085412-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
Lannett
TRIPELENNAMINE HYDROCHLORIDE
tripelennamine hydrochloride
TABLET;ORAL083557-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
Parke Davis
TRIPELENNAMINE HYDROCHLORIDE
tripelennamine hydrochloride
TABLET;ORAL083626-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
Impax Labs
TRIPELENNAMINE HYDROCHLORIDE
tripelennamine hydrochloride
TABLET;ORAL080785-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
Watson Labs
TRIPELENNAMINE HYDROCHLORIDE
tripelennamine hydrochloride
TABLET;ORAL080713-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot